(VIANEWS) – VASTNED BELGIUM (VASTB.BR), SPBK 1 NORDMØRE (SNOR.OL), ROCHE BOBOIS (RBO.PA) are the highest payout ratio stocks on this list.
We have collected information concerning stocks with the highest payout ratio up to now. The payout ratio in itself isn’t a promise of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. VASTNED BELGIUM (VASTB.BR)
78.85% Payout Ratio
Vastned Retail Belgium is a public regulated real estate company (RREC), the shares of which are listed on Euronext Brussels (VASTB). Vastned Retail Belgium invests exclusively in Belgian commercial real estate, more specifically in prime retail properties located on the best shopping streets in the major cities of Antwerp, Brussels, Ghent and Bruges. Furthermore, the real estate portfolio consists of inner-city shops outside of the premium cities, high-end retail parks and retail warehouses.
Earnings Per Share
As for profitability, VASTNED BELGIUM has a trailing twelve months EPS of €-1.62.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.29%.
2. SPBK 1 NORDMØRE (SNOR.OL)
50.15% Payout Ratio
SpareBank 1 Nordmøre provides various banking services in Norway. The company offers savings and deposit accounts; car, motorcycle, boat, and construction loans; and mortgages. It also provides business insurance products, which include liability, auto, mortgage, operating loss, asset, commercial, and project insurance products; personal insurance products, such as life, travel, and accidental insurance products; pension products; bank cards; payment and debt collection services; and mobile and online banking services. In addition, the company offers bank guarantees, trade credit products, and operating credit products for agriculture, as well as factoring, leasing, and repayment products and services. The company was founded in 1835 and is based in Kristiansund, Norway. SpareBank 1 Nordmøre is a subsidiary of SpareBank 1 Gruppen AS.
Earnings Per Share
As for profitability, SPBK 1 NORDMØRE has a trailing twelve months EPS of kr9.31.
PE Ratio
SPBK 1 NORDMØRE has a trailing twelve months price to earnings ratio of 14.5. Meaning, the purchaser of the share is investing kr14.5 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.44%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Apr 6, 2022, the estimated forward annual dividend rate is 5 and the estimated forward annual dividend yield is 3.94%.
Moving Average
SPBK 1 NORDMØRE’s worth is above its 50-day moving average of kr123.84 and higher than its 200-day moving average of kr125.67.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.9%, now sitting on 698M for the twelve trailing months.
3. ROCHE BOBOIS (RBO.PA)
33.88% Payout Ratio
Roche Bobois S.A. engages in the furniture design and distribution business worldwide. It provides living room products, such as sofas and sofa beds, coffee tables, armchairs, wall compositions, cocktail tables, TV units, bookcases, cabinets, side tables, consoles, and occasional furniture; dining room products, including chairs, stools, benches, sideboards, dining tables, columns, dressers, and dining room storage products; desks; bedroom products comprising beds, wardrobes, bedside tables, screens, complements, and other bedroom furniture products; outdoor furniture products; and lights, cushions, rugs, mirrors, decorative objects, and home furnishings, as well as other furniture products. The company offers its products under the Roche Bobois and Cuir Center brands. As of March 31, 2022, it operated 128 owned and 210 franchised stores in 56 countries worldwide, as well as an online store. The company was formerly known as Furn-Invest S.A.S. Roche Bobois S.A. was founded in 1960 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ROCHE BOBOIS has a trailing twelve months EPS of €1.98.
PE Ratio
ROCHE BOBOIS has a trailing twelve months price to earnings ratio of 19.19. Meaning, the purchaser of the share is investing €19.19 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.83%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 27.2%, now sitting on 377.35M for the twelve trailing months.
Volume
Today’s last reported volume for ROCHE BOBOIS is 222 which is 91.71% below its average volume of 2681.
Yearly Top and Bottom Value
ROCHE BOBOIS’s stock is valued at €38.00 at 01:05 EST, below its 52-week high of €41.00 and way above its 52-week low of €28.50.
Moving Average
ROCHE BOBOIS’s worth is above its 50-day moving average of €37.24 and way above its 200-day moving average of €34.22.
4. BOIRON (BOI.PA)
32.87% Payout Ratio
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds. Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €1.5.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 28.19. Meaning, the purchaser of the share is investing €28.19 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.87%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 1, 2022, the estimated forward annual dividend rate is 0.95 and the estimated forward annual dividend yield is 2.25%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 35.2%, now sitting on 522.03M for the twelve trailing months.
Yearly Top and Bottom Value
BOIRON’s stock is valued at €42.20 at 01:05 EST, way under its 52-week high of €53.20 and way above its 52-week low of €37.30.
Sales Growth
BOIRON’s sales growth is 17.2% for the ongoing quarter and 17.2% for the next.
